FDAFinal Rule
Medical Devices; Radiology Devices; Classification of the Liver Iron Concentration Imaging Companion Diagnostic for Deferasirox
HealthcareTechnology
Ad Space (leaderboard)
Summary
The FDA is classifying a new medical imaging tool that helps doctors measure iron levels in the liver of patients taking the drug deferasirox. This classification means the device can now be used in medical practice to help monitor whether this iron-reducing medication is working safely and effectively for patients who have too much iron in their bodies.
Key Points
- 1The FDA officially recognizes a liver iron imaging tool as a companion diagnostic, meaning it's designed to work alongside deferasirox treatment
- 2This imaging device helps doctors check iron buildup in patients' livers to ensure the medication is working and safe
- 3The classification allows hospitals and clinics to use this diagnostic tool to monitor patients who are taking deferasirox for iron overload conditions
- 4Patients with conditions like thalassemia or repeated blood transfusions who take deferasirox can now benefit from better monitoring of their iron levels
- 5The regulation establishes safety and effectiveness standards that manufacturers of this imaging device must follow
Impact Assessment
If you are a healthcare provider, this means you can now use this imaging device to monitor iron levels in patients taking deferasirox, improving treatment safety and effectiveness.
Impact Level
Moderate
Geographic Scope
National
Compliance Cost
Minimal
Who is Affected
Healthcare ProvidersManufacturersConsumers
Key Dates
Published
August 21, 2025
Regulatory Connections
Authorized By
Amends CFR Sections
21 CFR Part 860
This summary is for informational purposes only. It may not capture all nuances of the regulation. Always refer to the official text for authoritative information.
The Digest Network
Ad Space (rectangle)